-1753360817149.webp&w=3840&q=75)
2025 NOSCM | Future Directions in the Management of Small Cell Lung Cancer
0% Complete
Course Overview
Dr. Paul Bunn discussed the IMpower133 and CheckMate-153 trials, highlighting the efficacy of atezo and durva in SCLC.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Paul Bunn, MD
Accreditation
NA
